IDEXX provides diagnostic and software products and services for pet healthcare, self-described as a global leader in veterinary innovation.

David Evans Shaw

IDEXX

Neogen is a Belgian pharmaceutical company focused on providing a full scope of out-licensing and other pharmaceutical development services for clients worldwide.

Neogen

Virbac offers veterinarians, farmers, and pet owners a range of products and services focused on animal health, covering various species and diseases, self-described as contributing to the future of animal health.

Virbac

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Dechra Pharmaceuticals PLC

IDEXX Animana

ezyVet

IDEXX Small Animal Health

IDEXX Water Testing

Livestock Diagnostics

10,000 people, one global focus﻿ - enhancing the health and well-being of pets, people, and livestockWe are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of disease, it’s no wonder that what we do each day is more than just a job. There’s an energy across IDEXX that is contagious – where caring and committed people come together to make things better. IDEXX Laboratories, Inc. (NASDAQ: IDXX), a member of the S&P 500, is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. Headquartered in southern Maine, we conduct operations through more than 70 locations around the world and serve customers in over 175 countries.Our primary business focuses on pet health, a growing market around the world. Our products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. We also develop and manufacture diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water and milk. Please visit our website, IDEXX.com/careers, for further information and to view all of our job opportunities.

Metric
Company Name	IDEXX	Neogen	Virbac	Dechra Pharmaceuticals PLC
Symbol				DPH
MSH ID	COM:IDEXX	BE:NEOGEN	COM:VIRBAC	COM:DECHRA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Veterinary Care	Pharmaceuticals	Veterinary	Drug Manufacturers - General
Country	US	BE	FR	GB
Stage
Employee Count	7.37K			2.46K
Website	idexx.com	neogen.be	virbac.com	dechra.com
LinkedIn
Founders

Metric
Market Cap		56.12M
Enterprise Value
Monthly Web Traffic	253.55K
Web Traffic Growth	-0.32
Valuation
Raised Capital

Metric
Revenue				970.32M
Revenue (LTM)
Revenue (NTM)
Gross Profit				543.20M
EBITDA				125.00M
Operating Income				8.03M
Net Income				-35.55M
EPS				-0.32
Diluted EPS				-0.31
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.56
Operating Profit Margin				0.02
EBITDA Margin				0.13
Net Profit Margin				-0.04
Return on Equity				-0.03
Return on Assets				-0.02
Return on Capital Employed				0.01

COM:IDEXX

IDEXX

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-157.74
P/B Ratio				5.83
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				5.78
EV Multiple				63.88

Metric
Days Sales Outstanding
Days Payables Outstanding				158.91
Days Inventory Outstanding				238.97
Operating Cycle				308.09
Cash Conversion Cycle				149.18
Asset Turnover				0.49

Metric
Operating Cash Flow				81.04M
Free Cash Flow				42.43M
Cash Flow to Debt				0.13
Operating Cash Flow/Sales				0.08
Free Cash Flow Yield				0.01

Metric
Cash & Equivalents				94.80M
Accounts Receivable				-27.40M
Inventory				276.89M
Goodwill				426.23M
Debt to Capitalization				0.40
Debt to Assets				0.32
Current Ratio				2.85
Quick Ratio				1.33

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				-0.00
R&D to Revenue				0.12
SG&A to Revenue